To test that, we treated mice bearing BLCA tumors with IgG, anti-CD276 antibody, anti-PD-1 antibody or combination of anti-CD276 and anti-PD-1 antibodies (Fig. 7a). This evidence concerns the gene CD276 and bladder transitional cell carcinoma.